Gonadorelin


Generic Medicine Info
Indications and Dosage
Intravenous, Subcutaneous
Diagnosis of hypothalamic-pituitary-gonadal dysfunction
Adult: For the evaluation of gonadotropin deficiency, or residual gonadotropic function of the anterior pituitary following removal of pituitary tumour or surgery and/or irradiation: 100 mcg as a single dose via SC or IV inj. In females whom the phase of the menstrual cycle can be established: Perform test in the early follicular phase of menstrual cycle (days 1-7). Refer to detailed product guideline for information on the test methodology.
Reconstitution
Reconstitute vial labelled as 100 mcg with 1 mL of sterile water for inj. May refrigerate solution for up to 24 hours after reconstitution.
Contraindications
Pituitary adenoma. Pregnancy and lactation.
Adverse Reactions
Significant: Haemorrhagic infarction (pituitary apoplexy). Rarely, hypersensitivity and anaphylactic reactions.
Cardiac disorders: Rarely, tachycardia.
Eye disorders: Rarely, erythema of eyelid.
Gastrointestinal disorders: Rarely, nausea, abdominal discomfort.
General disorders and administration site conditions: Pain, injection site reactions (e.g. induration, irritation, inflammation, erythema).
Infections and infestations: Sepsis.
Nervous system disorders: Rarely, headache, dizziness.
Reproductive system and breast disorders: Menorrhagia.
Respiratory, thoracic and mediastinal disorders: Rarely, bronchospasm.
Skin and subcutaneous tissue disorders: Pruritus, rash. Rarely, urticaria.
Vascular disorders: Thrombophlebitis. Rarely, flushing.
Monitoring Parameters
Obtain serum LH 15 minutes and immediately before administration, then 15, 30, 45, 60, and 120 minutes after administration.
Drug Interactions
Androgens, estrogens, progestogens, or glucocorticoids may alter the response to gonadorelin. Gonadotropin levels may be transiently increased by spironolactone and to a lesser extent by methyldopa. Phenothiazines and dopamine antagonists may reduce response to gonadorelin. Gonadotropin levels may be suppressed by digoxin and oral contraceptives.
Action
Description: Gonadorelin is a synthetic form of the hypothalamic gonadotrophin-releasing hormone that stimulates the synthesis and release of follicle-stimulating hormone and luteinising hormone (LH) from the anterior pituitary gland.
Synonym: gonadotrophin-releasing hormone (GnRH); LH-releasing hormone.
Pharmacokinetics:
Distribution: Volume of distribution: Approx 10-15 L.
Metabolism: Rapidly hydrolysed in plasma.
Excretion: Via urine (as inactive metabolites). Terminal elimination half-life: Approx 10-40 minutes (IV).
Chemical Structure

Chemical Structure Image
Gonadorelin

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 638793, Gonadorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Gonadorelin. Accessed Feb. 24, 2021.

Storage
Store below 25°C.
MIMS Class
Trophic Hormones & Related Synthetic Drugs
ATC Classification
V04CM01 - gonadorelin ; Belongs to the class of diagnostic agents used to test for fertility disturbances.
References
Anon. Gonadorelin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/02/2021.

Buckingham R (ed). Gonadorelin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/02/2021.

Gonadorelin 100 mcg Powder for Solution for Injection; HRF 100 mcg (Intrapharm Laboratories Limited). MHRA. https://products.mhra.gov.uk. Accessed 03/02/2021.

Joint Formulary Committee. Gonadorelin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/02/2021.

Disclaimer: This information is independently developed by MIMS based on Gonadorelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in